SEATTLE, Sept. 10, 2015 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, announced today its support of World Sepsis Day 2015 and Sepsis Awareness Month. Scheduled for Sept. 13, World Sepsis Day is sponsored by the Global Sepsis Alliance and Sepsis Alliance in the U.S. to educate medical professionals, inform policymakers and generate awareness among the general public as to the immediate need for action to eliminate preventable deaths caused by sepsis.
As part of its initiatives, Immunexpress has signed the World Sepsis Declaration, adhering to its core messages of communication for increasing global awareness of sepsis, implementation of international sepsis guidelines to improve earlier recognition, and the development of more effective treatments.
"Sepsis is a severe health problem, yet it is still unknown and misunderstood by the public," said Roslyn Brandon, President and CEO of Immunexpress. "Every few seconds, someone in the world dies of sepsis, and the incidence is increasing. We support the Global Sepsis Alliance's efforts to reduce the incidence of sepsis through a coordinated effort that is absolutely critical at this time."
Sepsis is a life-threatening condition that arises when the body's response to infection damages its own tissues and organs. It is one of the most common and, at the same time, least recognized diseases throughout the world, affecting an estimated 20 to 30 million patients every year. Early identification and treatment of sepsis can save lives, reduce the negative impact of sepsis, as well as reduce the financial burdens to patients and the healthcare system.
Click here http://immunexpress.com/sepsis-diagnostics-video to watch video interviews of Immunexpress executives focused on introducing new technology to diagnose sepsis earlier and faster, U.S. clinicians recognized for their work in sepsis identification and treatment, and a sepsis survivor.
Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Immunexpress's SeptiCyte® technology quantifies directly from whole blood specific molecular markers from the patient's own immune system – the "host response." Detecting the host's septic immune response can diagnose sepsis earlier and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen. Immunexpress's pipeline includes monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer platforms. For more information visit www.Immunexpress.com.
SOURCE Immunexpress, Inc.